Wegovy vs Ozempic: What the Research Shows
Wegovy and Ozempic side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Wegovy if…
- you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[10]
- you want the label that includes liver disease: Wegovy has an accelerated-approval indication for MASH with moderate to advanced liver fibrosis in adults[10]
- you want the higher-dose weight product: Wegovy's maintenance dosage in adults is 1.7 mg or 2.4 mg (recommended) injected once weekly[10]
Consider Ozempic if…
- you want the diabetes-labelled product: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes[5]
- you want the label with a kidney indication: Ozempic is indicated to reduce sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease[5]
- you want the diabetes dosing range: Ozempic's maximum recommended dosage is 2 mg once weekly[5]
What they have in common
Spec comparison
Showing all 11 fields. Highlighted rows differ.
| Field | Wegovy | Ozempic |
|---|---|---|
| Class | Brand of Semaglutide (GLP-1 agonist) | Brand of Semaglutide (GLP-1 agonist) |
| Also called | Brand name of Semaglutide | Brand name of Semaglutide |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Ozempic, Wegovy, Rybelsus) | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 1 weeksubcutaneous · FDA label (Ozempic) | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | 23 human (19 randomized or controlled) of 27 summarised | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
What is the difference between Wegovy and Ozempic?
Ozempic's label opens with glycemic control: it is indicated alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes.[5]
Wegovy's label is built around weight: it is indicated to reduce excess body weight and maintain the reduction long term in adults and pediatric patients aged 12 years and older with obesity, among other uses.[10]
STEP 2 is the closest thing to a Wegovy-versus-Ozempic comparison. It randomised adults with overweight or obesity and type 2 diabetes to semaglutide 2.4 mg, semaglutide 1.0 mg or placebo for 68 weeks.[11]
In STEP 2, gastrointestinal adverse events were reported by 63.5% on 2.4 mg, 57.5% on 1.0 mg and 34.3% on placebo.[11]
Ozempic's cardiovascular evidence is SUSTAIN-6 in type 2 diabetes at high cardiovascular risk, where the primary outcome occurred in 6.6% on semaglutide and 8.9% on placebo.[12]
The same SUSTAIN-6 abstract reports significantly higher rates of retinopathy complications with semaglutide (hazard ratio 1.76).[12]
Dose ladders and devices on each label
Ozempic's label starts at 0.25 mg once weekly for 4 weeks and then moves to 0.5 mg.[5]
The Ozempic label's next step is 1 mg weekly, after at least 4 weeks on the 0.5 mg dose, when more glycemic control is needed.[5]
Ozempic's label allows a further step to 2 mg once weekly, but only after at least 4 weeks at 1 mg and only when more glycemic control is needed.[5]
For Wegovy, the label says patients tolerating 2.4 mg for at least 4 weeks may be stepped to a maximum of 7.2 mg weekly where more weight reduction is clinically indicated.[10]
The Ozempic label lists storage for single-patient-use pens that hold multiple weekly doses, and separately for single-dose prefilled syringes.[5]
Wegovy is no longer injection-only: its label now covers both an injection and tablets, with the tablets also indicated to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[10]
Shared warnings that apply to both
Ozempic is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.[5]
The Wegovy label says not to combine it with other semaglutide products or any other GLP-1 receptor agonist, so using both brands together is not recommended.[10]
Common questions
Is Wegovy the same as Ozempic?
They share the active ingredient but are separate products with separate labels. Ozempic is labelled as a diabetes medicine, to improve glycemic control in adults with type 2 diabetes, and Wegovy's weight-reduction label is quoted in the section above.[5]
Is Wegovy stronger than Ozempic?
Both are semaglutide. In STEP 2, gastrointestinal adverse events were reported more often on 2.4 mg than on 1.0 mg.[11]
Can I take Ozempic and Wegovy together?
No. The Wegovy label says concomitant use with other semaglutide-containing products is not recommended.[10]
Which one lowers cardiovascular risk?
Wegovy tablets are labelled to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[10]
Does Ozempic work for weight loss like Wegovy?
STEP 2 compared semaglutide 2.4 mg with 1.0 mg, the dose approved for diabetes treatment, and with placebo, for weight management in adults with overweight or obesity and type 2 diabetes.[11]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9PubMed search: (Ozempic[tiab]) AND (Wegovy[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet (London, England) · 2021PMID 33667417Accessed 2 Oct 2026
- 12Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026
Found an error? Report a correction.